Q-omics provides the consensus-scored SLFN14 profile across patient tissues and cancer cell-line models. SLFN14 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, SLFN14 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, SLFN14 RNA expression shows 15,348 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where SLFN14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLFN14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLFN14 survival associations across molecular data types. SLFN14 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLFN14 RNA expression–survival associations across cancer types. High SLFN14 expression shows unfavorable associations in KIRC and LGG, but favorable associations in SKCM, HNSC, CESC and BLCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for SLFN14 RNA expression.
This table summarizes SLFN14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SLFN14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLFN14 shows lower tumor expression in LUSC, LUAD, UCEC and THCA and higher tumor expression in KIRC and HNSC. The KIRC box plot shows higher SLFN14 RNA expression in tumor versus normal tissue (log2 FC = +0.075, t-test p < 0.001).
This table shows molecular features associated with SLFN14 in patient tissues and cancer cell lines. In patient samples, SLFN14 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLFN14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Lymphoma.
